BrightInsight provides the leading global regulated digital health platform for biopharma and medtech. Every line of code of our BrightInsight Platform is built under a Quality Management System to support and optimize regulated drugs, devices and software through integrated data and actionable insights to enable customers to drive increased patient adherence and engagement. The BrightInsight™ Platform uses software and services to capture, transmit and analyze data from CE-marked and FDA-regulated medical devices, combination products, apps and Software as a Medical Device, in compliance with global security, privacy and regulatory requirements. Deployed as a managed service, the platform accelerates time to market for biopharma and medtech companies, reduces the cost of implementation and maintenance versus a custom solution, and scales across products and global markets.
Curebase is a leading provider of decentralized clinical research software and services for digital therapeutics. Curebase enables any patient and any healthcare provider to be part of a clinical study, accelerating enrollment and enabling novel study designs with diverse populations. Curebase operates as a complete eClinical software platform, virtual research site, and full-service CRO.
Decimal.health is a specialized digital health consulting firm that creates and implements
strategies to launch and grow digital health products and services. Through our deep network
and expertise in US healthcare delivery and regulations, we help digital health businesses
navigate the complex DTx and FDA regulatory path and gain traction with investors and
Ieso is a data-driven AI healthcare company pioneering next-generation digital therapeutics to improve mental health outcomes and access to care.
The company is developing a pipeline of AI-driven evidence-based mental health assessment tools and solutions to democratize access to mental health therapy at scale. With a network of more than 600 fully qualified therapists, ieso provides virtual care (or telehealth) serving more than 20 million adults through the UK National Health Service (NHS), delivering more than 460,000 hours of cognitive behavioral therapy (CBT).
The company has analyzed over 500 million datapoints to decode the active ingredients of therapy to develop scalable digital therapeutics. ieso’s research has been published in several peer-reviewed journals including the Lancet and JAMA, shaping our understanding of scalable digital mental healthcare solutions.
TopLine Power® is what Simon-Kucher is all about. We help clients grow revenue through optimization of strategy, pricing, marketing, and sales across industries.
We are a thought leader in these topics at the intersection of digitalization and life sciences, positioning our clients to thrive in the healthcare industry of the future.
Dawn Health is a leading company in digital health specializing in the development of software as medical device (SaMD) and digital therapeutics (DTx). Partnering with the pharmaceutical industry and leveraging the Dawn Platform, Dawn Health accelerates the launch of digital solutions that improve the lives of people with chronic conditions.
Delve Health’s Clinical StudyPal is a multi-modal, end-to-end platform that supports virtual, hybrid, and traditional clinical trials through the collection of passive data from patient data sources like wearables, biosensors, and medical devices will drive innovation within the field.
Clinical StudyPal can integrate into virtually any source system, allowing for real-world data (RWD) to be captured in real-time, as well as automate a study staff’s workflow—significantly decreasing a clinical trial sites burden, while also lowering costs due to boosting efficiency.
We support the digital healthcare movement in order to provide access to diverse and underrepresented patient populations, worldwide. We work with a wide array of companies and organizations, including but not limited to pharmaceutical, general healthcare, clinical research organizations, insurance companies, medical device companies, as well as disease-specific therapeutic areas.
We set our sight on a simple, but powerful vision to advance life science services toward a healthier world.
The journey began when Water Street Healthcare Partners and JLL Partners joined forces to acquire and combine the most comprehensive platform of life sciences services in the industry. Together, we are EVERSANA.
We offer more than 500 clients – from start-ups to established global pharmaceutical leaders – the services they need to bring critical therapies to market while improving the lives of patients around the world.
Curavit is a “Virtual CRO” that designs and executes decentralized – or “virtual” – clinical trials. Curavit leverages emerging technologies in digital health, cloud computing, and data science to recruit, engage, and monitor diverse patient populations from wherever they live, work, or study; eliminating the need for physical infrastructure and travel, while increasing data quality. Curavit brings together the world’s leading researchers, enrolls previously untapped and underserved patient populations, applies machine learning algorithms to health and social engagement information to recruit participants, and leverages leading telehealth, patient data, and medical device technologies. Curavit’s central virtual site supports remote monitoring and is always audit ready.
DTxCC: a boutique consultancy focused solely on Digital Therapeutics and Digital Health commercialization
We specialize in go-to-market strategy development:
– Market Access and Reimbursement
– Business models development
– Data monetization
Our Payer Advisory Council provides actionable insight
Custom qualitative research
– One-one-one interviews
Advisory board meetings
– Live face-to-face meetings
Your Strategic Product Development Partner. Vynyl develops custom software for leading healthcare and insurance companies and institutions. Reimagine your products using Agile and design sprints. Build, launch, and run consumer-facing digital therapeutics, telemedicine, and diagnostics. Implement powerful security and comply with HIPAA, HITECH, SSAE, HL7, and more. Drive innovation with our practical approach to development, DevOps, cloud, product management, and design.
Urban DTx is pioneering effective, non-drugs, non-invasive, software interventions for anxiety. The DTx creates a personalised anxiety management plan with timely AI assistance, to bring positive health outcomes in 4 and 14 weeks on GAD-7 scale.
Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. are the US-based indirect subsidiaries of the global healthcare company Otsuka Pharmaceutical Co. Ltd with the corporate philosophy: “Otsuka – people creating new products for better health worldwide.” Otsuka’s US companies share a deep commitment to the development and commercialization of innovative products in the spaces of neuroscience, nephrology, and digital medicine. We have an unwavering belief in doing more and going above and beyond – under any circumstances – so that patients can push past the limitations of their disease and achieve more than they thought was possible every day.
DTx West has returned! Bringing you 3 full days of cutting-edge content and an industry leading speaker faculty, this event provides you with a one-stop shop of all things digital therapeutics ensuring you leave the event with key takeaways and the knowledge to accelerate your own digital journey. Come along to DTx West 2023 and get exclusive access to the latest and greatest in digital medicine. We look forward to seeing you in February!
The time has come to meet in-person once again! Join your peers for live presentations and engaging discussions. DTx West will be diving into key areas such as Commercialization, Regulation, Clinical Trials, Patient Insights, Provider Adoption, User Engagement, Partnerships and more. No matter where your interest lies, we’ve got you covered.
Experts from every stakeholder within the digital therapeutics space will be coming down to California in February 2023. Calling to every corner of the industry, join your peers from leading DTx companies, Pharma, Payers, Providers, Government Bodies, Academia, Policy Makers and more. Step away from the screen for 3 days of industry-defining discussions and catch up with old and make new connections within the field.
“This year DTx has been a great opportunity to interact with thought leaders of the industry, learn from them and establish partnerships with them. I think the education you receive here is really great.”
“DTx East 2022 has been a phenomenal experience, looking forward to DTx West in 2023”
“The digital therapeutics industry as a whole is incredibly collaborative, and the DTx conference series provides the ideal platform for all stakeholders to come together, share ideas, and leave with the ability to have the most impact on patients’ lives”
“I always find the topics are very clear, concise and topical. You’re really following the conversations that are happening and so a lot of times when I look at the agenda I think ‘these are exactly all the things that I want to talk or hear about’”
“DTx East was by far the best digital conference I’ve been to”
2023 Speaker Faculty
Anand is a respected global digital health leader—most known for his insights on and experience with technology, strategy and regulatory policy. Anand has been instrumental in WellDoc’s success and the development of BlueStar®. Since joining WellDoc in 2008, he has held core leadership positions that included Chief Data Science Officer, President and Chief Operations Officer. He holds an MS and a PhD in electrical and computer engineering, and an MBA from Carnegie Mellon University.
Dr. Robinson leads Moffitt’s Center for Digital Health which
leverages the tools of IT, Health Data Services, and Digital
Innovation to expand Moffitt’s ecosystem to deliver on consumer-
oriented, real-world solutions for clinical practice, research,
education, and administrative processes. The Center for Digital
Health creates and tests new services, programs, partnerships, and
technologies that leverage digital innovations, while challenging the
status quo to reduce the cost of care, improve quality, increase
access to care, and enhance the patient experience. In addition, he
directly cares for Moffitt patients as part of the Internal and Hospital
Previously, Dr. Robinson was the Chief Transformation Officer and
Senior Vice President of Consumerism at ChristianaCare, one of the
largest health systems in the mid-Atlantic. He was responsible for
the transformation of health care delivery to advance population
health initiatives and the move from volume-based to value-based
care with a special focus on developing and managing
ChristianaCare’s consumerism and digital strategies.
Dr. Robinson is an associate professor at University of South
Florida’s Morsani College of Medicine. He is also a fellow of the
American College of Physicians and a senior fellow of the Society of
Hospital Medicine. He holds a medical degree from the David
Geffen School of Medicine at the University of California, Los
Angeles; an MBA with an emphasis in health care management from
the Wharton School at the University of Pennsylvania; and a
master’s degree in health policy research also from the University of
Scott Barclay is a Managing Director at Insight Partners, where he focuses on investments in healthtech. His Computational Care thesis envisions the future of US and global healthcare built at the intersection of empathy and scalable technology.
Scott’s early career traversed capital markets with Banc of America Securities in Europe and the US, The Boston Consulting Group, and CVS Health. At CVS and then after, Scott helped create and scale the nation’s e-Prescribing ecosystem, running iScribe (acq Allscripts) and as Chief Strategy Officer of Surescripts.
Prior to Insight, Scott built his investing career as a healthcare angel investor and advisor (NaviHealth, Doximity, Elation) and, from 2015 – 2020, as a Partner at DCVC, a world-class early-stage deep tech venture capital firm, where he was a director or observer on the Boards of companies like Carbon Health, Freenome, SafelyYou, and many others.
Scott holds a BA in History from the University of Virginia and an MBA from INSEAD in Fontainebleau, France.
Daniel Daugaard is the CEO and Founder of Dawn Health. Bringing sound experience from the Life Science Industry, Daniel founded Dawn Health in 2016, where the company has expanded at a rapid pace under his inspiring leadership, expertise and deep-rooted passion to change the lives of patients.
In the past two years, he and the Dawn Health team have raised substantial investments, to deploy their product platform on a global scale and secured a board of directors consisting of the highest calibre leaders from the tech industry. Daniel has grown his team by 350% in 2022 and fostered new strong partnerships with the world’s leading pharma companies, through which Dawn Health provides DTx and SaMD products build from cutting-edge software, helping patients with chronic diseases to live better lives.
Daniel has successfully transformed his Danish-based company from a design and software powerhouse into a fully-fledged product company with a clear aim to accelerate the development of regulated software products leveraged by the Dawn Platform.
David Matthews, PhD, has 15 years of experience in pharmaceuticals, medical technology, and medical research.
Before joining BrightInsight, David was a Partner in the Healthcare, Commercial, and Corporate Finance & Strategy Practices at Boston Consulting Group (BCG), where he helped lead the West Coast Medical Technology business. He served a range of healthcare clients on strategy, commercial, R&D, medical & regulatory affairs, and transformation topics, including standing up medical SaaS businesses. He was selected as an Ambassador to BCG’s internal thinktank, the Henderson Institute, where he designed and published on new economic models for biopharma products, including building the Netflix model for curative therapies. While at the firm, he received several internal awards and recognition for thought leadership, apprenticeship, and client success.
Prior to his time at BCG, David was a computational neuroscientist, with more than 20 publications and conference proceedings across machine learning, bioinformatics, brain imaging, neuroanatomy, and health economics. He has consulted independently on machine learning applications in biomedicine, built an early telemedicine app for automated melanoma detection, and taught neuroscience as an Adjunct Professor.
David holds a PhD in Computational Neurobiology from The University of California, San Diego and the Salk Institute, where he was a National Science Foundation (NSF) Research Fellow and NSF Center for Theoretical Biological Physics Fellow; and a Bachelor with honors in Molecular Biology, and minors in Bioengineering and Neuroscience, from Princeton University.
Jamie’s goal is to help others lead healthier, happier lives through improving access to quality healthcare. She is currently working towards the latter as the Vice President, Network Strategy & Operations at Maven Clinic, scaling the largest virtual clinic for women’s and family health.
Prior to Maven, Jamie served in business development, operations, and service design roles at Mount Sinai Health Partners, focused on commercializing specialty care bundles and value-based care models. Jamie started her career as a management consultant within Deloitte’s Strategy & Operations practice, focused on product commercialization and growth strategy across the healthcare, materials science, and development sectors.
Jamie graduated magna cum laude as a Merrill Presidential Scholar from Cornell University and holds a Master of Business Administration from Columbia Business School.
Dr. Maricich is a licensed, board-certified physician, investor, clinical developer, and strategist. He works
to improve patient health and our healthcare system by investing in, advising, and providing leadership
at innovative firms. At Pear Therapeutics, he leads the Clinical, Regulatory, and Quality groups as the
Chief Medical Officer and Head of Development. He leads and manages the development programs
from Discovery/TPP stage, through Translational, Clinical Development, Regulatory submission, and
review as well as Medical Affairs. In addition to overseeing subsequent pipeline programs across a
broad-spectrum of disease areas, he has led the reSET, reSET-O, and Somryst programs.
Prior to joining Pear, Dr. Maricich worked with and lead successful teams and programs at Healthcare &
Life Science/biotech (HLS) firms, including Corixa (acquired by GlaxoSmithKline), Xdynia (acquired by
Cavion), Cavion (acquired by Jazz Pharmaceuticals) and AWS. He founded a digital health firm while a
med student that used AI and NLP to structure clinical data.
Dr. Maricich completed his education and training at Harvard University, the University of Washington,
the University of Notre Dame, and the University of Virginia.
Dr. Jenna Carl is a clinical psychologist who specializes in the research and treatment of anxiety, depression, insomnia, and related mental health disorders. She has authored more than 30 peer-reviewed publications, and has presented her research and clinical trainings at leading international conferences, such as the Association for Behavioral and Cognitive Therapies, World Congress for Behavioral and Cognitive Therapies, and the American Psychological Association (APA). She serves as Chair of the APA’s Division 12 Presidential Task Force on the integration of technology and mental health treatment.
As the Chief Medical Officer at Big Health, Dr. Carl is responsible for developing evidence-based digital therapeutics for common mental health conditions that can be implemented within large employers, health plans, and health systems. She obtained her PhD in clinical psychology from Boston University, with training in the Center for Anxiety and Related Disorders at Boston University, Massachusetts General Hospital, Harvard Medical School, and the VA Health System’s National Center for Innovation to Implementation.
The 6th annual DTx West will take place at the Crowne Plaza Hotel Foster City – San Mateo.
Address: 1221 Chess Dr, Foster City, CA 94404, United States
Tucked away just 9 miles from San Francisco International Airport, come along and join your peers for live presentations, engaging discussions and face-to-face networking.
We are pleased to announce that the DTx team have secured a reduced room rate at the Crowne Plaza for event attendees.
These rooms are available at $249 per night plus taxes and are available to book HERE
All booking queries and cancellations must be discussed directly with the hotel.
HOW TO GET THERE
Taxi – 10-15 minutes from San Francisco International Airport
Please contact email@example.com if you have any questions about the venue or accommodation.
We look forward to welcoming you in San Mateo in February.
Partner with us
The DTx summits are the premier events for senior executives from DTx companies, Pharma, Policy Makers, Investors, HCPs and Payers.
DTx West 2023 is the twelth summit in the US DTx series. We anticipate over 450 people in attendance, which is what our attendees and partners tell us is the optimum size.
We believe that getting the right mix of partners is critical for a successful summit for you and our attendees. The DTx summit provides a rare opportunity to showcase your business to a world-class audience.
You will be impressed with our service and truthfulness. We will be honest with you throughout the process from deciding which option is right for you to delivery on-site.
Get in touch today to learn more and avoid missing out!
Register for the Event
For pricing and booking options please click the button to go to the registration page.